LENZ shares surge 12.17% after hours on Sarah Jessica Parker partnership for VIZZ campaign.
ByAinvest
Wednesday, Jan 14, 2026 4:31 pm ET1min read
LENZ--
LENZ Therapeutics surged 12.17% in after-hours trading following the announcement of its "Make it VIZZable" consumer campaign featuring Sarah Jessica Parker as a brand ambassador. The partnership leverages Parker’s relatable experience with age-related blurry near vision and her endorsement of VIZZ, a once-daily eye drop designed to replace reading glasses. The campaign, highlighting Parker’s personal testimonials and the product’s clinical efficacy, aims to broaden VIZZ’s market reach and reinforce its positioning as a convenient solution for presbyopia. This strategic move enhances brand visibility and consumer trust, aligning with the stock’s sharp rise as investors anticipate increased adoption and revenue potential.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet